Competitive and Non-Competitive Antagonism

Antagonists reduce the effect of an agonist, but they do so in fundamentally different ways. A competitive antagonist fights the agonist for the same site and can be overcome by enough agonist; a non-competitive antagonist disables the response by other means and cannot simply be outcompeted. Telling the two apart is a classic exercise in receptor pharmacology.

Definition

Competitive antagonism is reversible inhibition in which the antagonist and agonist compete for the same binding site, so increasing the agonist concentration can fully overcome the block; non-competitive antagonism reduces the maximal achievable response by a mechanism that the agonist cannot fully surmount, whether through irreversible occupancy of the site or action at a separate site or downstream step.

Scope

This topic covers the two principal modes of receptor antagonism—competitive (reversible, surmountable) and non-competitive (including irreversible orthosteric and certain allosteric mechanisms, generally insurmountable)—and the way each reshapes the agonist concentration-response curve. It includes the quantitative analysis used to identify competitive antagonism. It is reference pharmacodynamics and gives no dosing or treatment instructions.

Core questions

• How does a competitive antagonist shift the agonist concentration-response curve?
• Why can a competitive block be overcome by more agonist but a non-competitive block cannot?
• What distinguishes surmountable from insurmountable antagonism?
• How is competitive antagonism quantified and confirmed experimentally?

Key concepts

• Competitive (surmountable) antagonism
• Non-competitive (insurmountable) antagonism
• Irreversible orthosteric antagonism
• Parallel rightward curve shift
• Depression of maximal response
• Schild plot and pA2
• Reversibility of binding

Key theories

Schild analysis

A quantitative method in which the rightward shift of the agonist concentration-response curve produced by increasing antagonist concentrations is analysed to confirm competitive antagonism and estimate the antagonist's affinity (pA2).

Operational analysis of antagonism

Use of the operational model of agonism to interpret how reversible and insurmountable antagonists alter the position and maximum of concentration-response curves, distinguishing modes of antagonism within a unified efficacy framework.

Mechanisms

A competitive antagonist binds reversibly to the same site as the agonist; because the two compete by mass action, raising the agonist concentration restores occupancy and the maximal response is preserved, so the agonist concentration-response curve is shifted to the right in parallel without a fall in its plateau—the hallmark of surmountable antagonism. The size of that shift increases with antagonist concentration in a defined way, which Schild analysis exploits to confirm competition and to estimate the antagonist's affinity. Non-competitive antagonism, by contrast, reduces the maximal response that the agonist can produce. This occurs when an antagonist binds the orthosteric site irreversibly (or dissociates so slowly that it cannot be displaced within the experiment), removing a fraction of receptors from the pool the agonist can use, or when an antagonist acts at a separate site or a downstream step so that more agonist cannot fully restore the effect; such block is described as insurmountable and is reflected in a depressed curve maximum. Some allosteric agents producing strong negative modulation can also appear non-competitive.

Clinical relevance

The competitive-versus-non-competitive distinction explains why the effect of some antagonists can be overcome by raising agonist availability while others cannot, and it is a standard way of characterising how an antagonist acts on a receptor system. These are reference-level pharmacological principles and are not guidance on selecting, combining, or dosing medicines.

Evidence & guidelines

Antagonism is characterised through established laboratory pharmacology methods, principally Schild and operational analysis of concentration-response data; the associated terminology is standardised by the International Union of Basic and Clinical Pharmacology (IUPHAR) and standard texts rather than by clinical guidelines.

History

The quantitative study of antagonism was shaped by Gaddum's work on competing drugs and by Schild's 1947 introduction of the pA scale and the analysis that bears his name, which gave pharmacologists a rigorous test for competitive antagonism and a measure of antagonist affinity. Black and Leff's operational model later provided a general framework within which both surmountable and insurmountable antagonism could be interpreted, and Colquhoun's mechanistic analyses connected these behaviours to the underlying binding and gating of receptors.

Debates

Is a depressed maximum always non-competitive antagonism?

A fall in the agonist's maximal response can reflect irreversible or pseudo-irreversible orthosteric block, action at a separate site, or strong negative allosteric modulation; distinguishing these mechanisms from one another, and from artefacts of slow equilibration, requires careful kinetic and analytical work rather than the curve shape alone.

Key figures

• John H. Gaddum
• Heinz O. Schild
• James W. Black
• Paul Leff
• David Colquhoun

Seminal works

• schild-1947
• black-leff-1983

Frequently asked questions

Why can a competitive antagonist be overcome by more agonist but a non-competitive one cannot?

A competitive antagonist occupies the agonist's site reversibly, so adding more agonist outcompetes it and restores the full response; a non-competitive antagonist removes receptors from use or acts elsewhere, so extra agonist cannot fully recover the maximal effect.

What does a Schild analysis show?

It examines how much the agonist concentration-response curve is shifted to the right by increasing concentrations of an antagonist; a defined linear relationship confirms competitive antagonism and yields an estimate of the antagonist's affinity (pA2).